Focus: Forest Devices is a Pittsburgh-based biotech company developing a portable EEG-based device with machine learning for rapid diagnosis of large vessel occlusions and stroke subtypes. The company operates at the intersection of neurology and cardiovascular medicine with a novel diagnostic platform.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Forest Devices to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic SSRI generating majority of company revenue; post-loss-of-exclusivity positioning indicates commodity product with limited growth potential.
Help build intelligence for Forest Devices
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Forest Devices's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Branded racemic citalopram nearing loss of exclusivity; modest revenue contribution with predictable cliff risk.
Fixed-dose combination analgesic in pre-launch phase; minimal revenue contribution and niche indication.
Narrow-therapeutic-index bronchodilator post-LOE with negligible Part D spend.
Combination antimicrobial agent in pre-launch phase with no disclosed revenue.
Sympathomimetic amine post-LOE with regulatory restrictions and likely minimal commercial focus.
Centrally-acting muscle relaxant in pre-launch phase; indicates portfolio breadth but undefined commercial strategy.
Duplicate theophylline product in pre-launch phase; unclear commercial differentiation from ELIXOPHYLLIN.
Extended-release sympathomimetic post-LOE; duplicate indication with PHENDIMETRAZINE TARTRATE suggests unfocused strategy.
99 discontinued, 8 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub